Dr. Steven Chang Joins OneMedMarket’s Advisory Board

OneMedMarket announced that Dr. Stephen Chang PhD will be joining OneMedMarket LLC as the co-chairman of its Scientific Advisory Board.

Chang announced his retirement from New York Stem Cell Foundation (NYSCF) this week where he served in the role as Senior VP of Strategic initiatives, where he had overall responsibility for planning, coordinating, and managing the activities of the research department that included a staff of 40. He was involved in executing dozens of contracts with leading pharmaceutical and other life sciences companies ranging from basic science to the development of therapeutics.

Chang had served in this role at NYSCF for seven years, a period which the organization grew from a small organization employing 6 researchers. He will continue to serve as a consultant to NYSCF.  

“After 7 years, it was time for a transition” said Chang.  “My time at the NYSCF was very rewarding. What I enjoyed most was developing the staff.  Nothing has given me greater satisfaction than helping talented young scientists develop into their full potential.”

“We are truly pleased to have his active engagement in the innovative initiatives of OneMedMarket” said Brett Johnson, Founder and CEO.  “Steve has served on our advisory board over the past four years and has been a source of great insight.  As we develop more research oriented activities such as our Healthcare Microcap Report where we are focused on truly finding the most promising companies and technologies, Steve’s understanding of the science is invaluable. Getting more of his time and focus is very exciting.”

“We have one of the most talented advisory boards in medicine, but haven’t had the bandwidth to fully utilize such. Steve’s new role enables us to do so” said Johnson.

Chang will co-chair the board along with Jonathan Steinberger MD, the founding co-chair of the advisory board. “I am pleased to see an expansion of our advisory board. He brings a terrific perspective and I look forward to working with him to strengthen and broaden the board” said Steinberger who is an assistant professor at OHSU’s Dotter Interventional Institute and the Knight Cardiovascular Institute in Portland Oregon.

Chang’s career has been spent at the bleeding edge of science and translating it to the clinic. His passion is tackling the most difficult problems of our time that can use novel technology to solve.  

The OneMedMarket advisory board is an ideal fit for Steve, in his capacity as co-chair he will actively review the companies and technologies OneMedMarket works with on various projects and will also serve as Science Editor of the OneMed Sentinel. He also plans to attend scientific and investment conferences around the world to identify the companies and technologies shaping the future of health and medicine.“He will play an important role to identify undervalued companies for our Healthcare MicroCap Report and identifying technologies for our China BioVentures initiative,” said Johnson.

Chang is regarded as a pioneer in gene therapy and cell therapy and was founding scientist of Viagene, a company sold to Chiron and later purchased by Novartis.  He has over 60 patents to his credit on basic technologies in the areas of gene therapy, cell therapy and regenerative medicine.

Dr. Chang’s background is distinguished. He received his BS in Zoology and Cell Biology from the University of Michigan and his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine. Areas of research interest include translational applications of basic science and pharmaceutical products in regenerative medicine.

Prior to joining NYSCF, Dr. Chang served as Chief Scientific Officer of Stemgent during the company’s founding in 2008. He was previously the CEO of Multicell Technologies and continues as a director of this company. He is also on the board of Histogen, Inc.